|
16th March 2018
from 10:30 – 11:00 and from 15:30-16:00 in the coffee break area in front of the Plenary Hall |
|
FVIII and FIX inhibitors in people living with hemophilia in Cameroon, Africa: a preliminary study
Marie Pauline Ngo Balôgôg Biboum (Cameroon) |
|
Immune tolerance in patients with hemophilia
A and inhibitors: preliminary results of the Brazilian Immune Tolerance
(BrazIT) Study
Ricardo Camelo (Brazil) |
|
INITIATE (Individualized ITI based on FVIII
protection by VWf): A prospective, randomized, double-blind trial of
lot-matched vs random-lot factor VIII (FVIII) concentrate for ITI
Jonathan Ducore (USA) |
|
FVIII expression under the control of its native promoter for hemophilia A gene and cell therapy
Rosella Famà (Italy) |
|
Case study of 22-year-old man with severe hemophilia A and long-standing inhibitor
Edward Laane (Estonia) |
|
The sudden appearance of inhibitors in a
severe haemophilia B previously treated patient after the switch to
albutrepenonacog alpha
Samantha Pasca (Italy) |
|
Acquired haemophilia at Chris Hani Baragwanath Academic Hospital
Moosa Patel (South Africa) |
|
Thrombocytopenia in association with an alloantibody in type 3 Von Willebrand’s disease
Irene Regan (Ireland) |
|
Microparticles estimation as predictive tests for monitoring bypassing agents in haemophilia patients with inhibitors
Puja Soni (India) |
